These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 1682042

  • 1. Combination therapy with adriamycin and interleukin 2 augments immunity against murine renal cell carcinoma.
    Gautam SC, Chikkala NF, Ganapathi R, Hamilton TA.
    Cancer Res; 1991 Nov 15; 51(22):6133-7. PubMed ID: 1682042
    [Abstract] [Full Text] [Related]

  • 2. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [Abstract] [Full Text] [Related]

  • 3. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
    Iguchi M, Matsumoto M, Hojo K, Wada T, Matsuo Y, Arimura A, Abe K.
    Jpn J Clin Oncol; 2009 May 01; 39(5):303-9. PubMed ID: 19336449
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models.
    Amagai Y, Matsumoto M, Hojo K, Iguchi M, Wada T, Tanaka H, Ide N, Kato A, Shichijo M, Abe K.
    Jpn J Clin Oncol; 2010 Jun 01; 40(6):503-7. PubMed ID: 20106881
    [Abstract] [Full Text] [Related]

  • 5. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
    Plum SM, Hanson AD, Volker KM, Vu HA, Sim BK, Fogler WE, Fortier AH.
    Clin Cancer Res; 2003 Oct 01; 9(12):4619-26. PubMed ID: 14555538
    [Abstract] [Full Text] [Related]

  • 6. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
    Iigo M, Sakurai M, Tamura T, Saijo N, Hoshi A.
    Cancer Res; 1988 Jan 15; 48(2):260-4. PubMed ID: 2446744
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
    Hillman GG, Younes E, Visscher D, Hamzavi F, Kim S, Lam JS, Montecillo EJ, Ali E, Pontes JE, Puri RK, Haas GP.
    Clin Cancer Res; 1997 Oct 15; 3(10):1799-806. PubMed ID: 9815566
    [Abstract] [Full Text] [Related]

  • 8. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.
    Saffran DC, Horton HM, Yankauckas MA, Anderson D, Barnhart KM, Abai AM, Hobart P, Manthorpe M, Norman JA, Parker SE.
    Cancer Gene Ther; 1998 Oct 15; 5(5):321-30. PubMed ID: 9824052
    [Abstract] [Full Text] [Related]

  • 9. [Antitumor activity of UFT against murine renal cell carcinoma: a study on the suppression tumor metastases].
    Fujioka T, Hasegawa M, Ishikura K, Nomura K, Okamoto T, Tanji S, Koike H, Kubo T.
    Gan To Kagaku Ryoho; 1990 Oct 15; 17(10):2031-6. PubMed ID: 2221926
    [Abstract] [Full Text] [Related]

  • 10. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity.
    Wang L, Qi X, Sun Y, Liang L, Ju D.
    Cancer Gene Ther; 2002 Oct 15; 9(10):819-24. PubMed ID: 12224022
    [Abstract] [Full Text] [Related]

  • 11. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J, Hu P, Khawli LA, Epstein AL.
    Cancer Res; 2003 Dec 01; 63(23):8384-92. PubMed ID: 14679000
    [Abstract] [Full Text] [Related]

  • 12. [Synergistic role between rhIL-2 and adriamycin long circulating temperature-sensitive liposome in targeting therapy on tumor].
    Dong LF, Mei HS, Song SX, Lu ZJ.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 May 01; 21(3):296-300. PubMed ID: 15862144
    [Abstract] [Full Text] [Related]

  • 13. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y, Kono T, Yasumoto R, Kishimoto T, Wang CY, Haas GP, Nishisaka N.
    J Immunother; 2001 May 01; 24(3):205-11. PubMed ID: 11394497
    [Abstract] [Full Text] [Related]

  • 14. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft.
    Berlion M, Arvelo F, Leonce S, Bourgeois Y, Rigaudy P, Bizzari JP, Poupon MF.
    In Vivo; 1993 Mar 01; 7(5):399-405. PubMed ID: 7906553
    [Abstract] [Full Text] [Related]

  • 16. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
    McIntosh JK, Mulé JJ, Krosnick JA, Rosenberg SA.
    Cancer Res; 1989 Mar 15; 49(6):1408-14. PubMed ID: 2784349
    [Abstract] [Full Text] [Related]

  • 17. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.
    Wang J, Nakamoto T, Kasaoka Y, Usui T, Hamada H.
    Hiroshima J Med Sci; 2000 Mar 15; 49(1):73-82. PubMed ID: 10824460
    [Abstract] [Full Text] [Related]

  • 18. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
    Hornung RL, Back TC, Zaharko DS, Urba WJ, Longo DL, Wiltrout RH.
    J Immunol; 1988 Nov 15; 141(10):3671-9. PubMed ID: 2460546
    [Abstract] [Full Text] [Related]

  • 19. Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas.
    Ho RL, Maccubbin D, Zaleskis G, Krawczyk C, Wing K, Mihich E, Ehrke MJ.
    Oncol Res; 1993 Nov 15; 5(9):373-81. PubMed ID: 8038458
    [Abstract] [Full Text] [Related]

  • 20. Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy.
    Salup RR, Back TC, Wiltrout RH.
    J Immunol; 1987 Jan 15; 138(2):641-7. PubMed ID: 3491854
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.